|
References: L
- Lacassie, Y., B. Curotto, M. A. Alliende, I. de Andraca, and A. Zavala. 1984. Evaluacion preliminar del tratamiento con acido folico en dos pacientes con retraso mental ligado al sexo y
macroorquidismo. Rev. Med. Chil. 112:469-473.
- Lachiewicz, A. M., and D. V. Dawson. 1994. Do young boys with fragile X syndrome have macroorchidism? Pediatrics 93:992-995.
- Lafferty, J. E., and J. N. Constantino. 1998. Fluvoxamine in selective mutism [letter]. J. Am. Acad. Child Adolesc. Psychiatry 37:12-13.
- Langee, H. R. 1989. A retrospective study of mentally retarded patients with behavior disorders who were treated with carbamazepine. Am. J. Ment. Retard. 93:640-643.
- Lappin, R. I., and E. L. Auchincloss. 1994. Treatment of the serotonin syndrome with cyproheptadine [letter]. N. Engl. J. Med. 331:1021-1022.
- Larson, J., C. N. Quach, B. Q. LeDuc, A. Nguyen, G. A. Rogers, and G. Lynch. 1996. Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats. Brain Res. 738:353-356.
- Leboyer, M. 1990. A double blind study of naltrexone in infantile autism. Presented at the Consensus Conference on Biological Basis and Clinical Perspective in Autism, Troina, La Citta dell'Oasi,
Sicilia, October 19.
- Leckman, J. F. 1987. Medications in fragile X children. Presented at the First National Fragile X Conference, Denver, December 3-4.
- Leckman, J. F., D. J. Cohen, J. M. Dertner, S. Ort, and D. F. Harcherik. 1984. Growth hormone response to clonidine in children age 4-17: Tourette's syndrome vs. children with short stature. J. Am.
Acad. Child Psychiatry 23:174-181.
- Leckman, J. F., J. Detlor, D. F. Harcherik, S. Ort, B. A. Shaywitz, and D. J. Cohen. 1985. Short and long-term treatment of Tourette's syndrome with clonidine: A clinical perspective. Neurology
35:343-351.
- Leckman, J., M. Hardin, M. Riddle, J. Stevenson, S. Ort, and D. Cohen. 1991. Clonidine treatment of Gilles de la Tourette's syndrome. Arch. Gen. Psychiatry 48:324-328.
- Lejeune, J. 1982. Is the fragile X syndrome amaenable to treatment? [letter]. Lancet 1:273-274.
- Lejeune, J., M.-O. Rethore, M. C. de Blois, and A. Ravel. 1984. Assay of folic acid treatment in fragile-X syndrome. Ann. Genet. 27:230-232.
- Lepola, U., E. Leinonen, and H. Koponen. 1994. Citalopram in anxiety disorder of childhood and adolescence [letter]. Eur. Child Adolesc. Psychiatry 3:277-279.
- ---. 1996. Citalopram in the treatment of early-onset panic disorder and school phobia. Pharmacopsychiatry 29:30-32.
- Levine, R. A., L. P. Milles, and W. Lovenberg. 1981. Tetrahydrobiopterin in striatum: Localization in dopamine nerve terminals and role in catecholamine synthesis. Science 214:919-921.
- Lipkin, P. H., I. J. Goldstein, and A. R. Adesman. 1994. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch. Pediatr. Adolesc. Med. 148:859-861.
- Livingston, M. G. 1994. Risperidone. Lancet 343:457-460.
- Lombroso, P. J., L. Scahill, R. A. King, K. A. Lynch, P. B. Chappell, B. S. Peterson, C. J. McDougle, and J. F. Leckman. 1995. Risperidone treatment of children and adolescents with chronic tic
disorders: A preliminary report. J. Am. Acad. Child Adolesc. Psychiatry 34:1147-1152.
- Luxem, M., and E. Christopherson. 1994. Behavioral toilet training in early childhood: Research practice and implications. J. Dev. Behav. Pediatr. 15:370-378.
- Lynch, G., M. Kessler, G. Rogers, J. Ambros-Ingerson, R. Granger, and R. S. Schehr. 1996. Psychological effects of a drug that facilitates brain AMPA receptors. Int. Clin. Psychopharmacol. 11:13-19.
- Lynch, G., R. Granger, J. Ambros-Ingerson, C. M. Davis, M. Kessler, and R. Schehr. 1997. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp.
Neurol. 145:89-92.
|
This article is not intended to give medical advice for individual cases. Any change in medical treatment
should be done in consultation with appropriate medical personnel. This article is written for medical professionals. Some of the terms will be unfamiliar to those who are not trained in medical fields.
*This article is from the chapter on treatment in the 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research edited
by Randi Jenssen Hagerman, M.D. and Paul Hagerman, M.D., Ph.D., to be published May 2002. It is included with permission from The Johns Hopkins University Press. References to other chapters refer to chapters in
the book which are not included as part of this website.
The complete 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research can be ordered from the National Fragile X Foundation by calling
1-800-688-8765 or from The Johns Hopkins University Press at 1-800-537-5487.
|
|
Medical Follow-up Pharmacotherapy Future Prospects
Outline Medications Medical Conditions
References: A, B, C, D, EF, G, H, IJ, K, L, M, NOP, QR, S, T, UVWXYZ
|
